Full text is available at the source.
Abstract
Tuberculosis (TB) is the leading cause of death from curable infectious diseases worldwide.
- Multidrug resistant (MDR) and extensively drug resistant (XDR) TB are significant global health concerns.
- There is an urgent need for new anti-TB drugs to combat these resistant strains.
- Enzymes critical for the growth of Mycobacterium tuberculosis, such as those involved in DNA and ATP production, are potential drug targets.
- Current progress in drug discovery focuses on inhibitors of enzymes like ribonucleotide reductase, DNA gyrase, ATP synthase, and thymidylate kinase.
- The review discusses challenges and opportunities in developing innovative tuberculostatic agents.
Simplified